Regulatory T cells in allogeneic transplantation

同种异体移植中的调节性T细胞

• 批准号: 8903997
• 负责人: Robert S Negrin
• 金额: $ 51.42万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-01 至 2016-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8903997
• 关键词: Acute; Adoptive Transfer; Allogenic; Animal Model; Animals; Antigens; Asthma; Autoimmune Diseases; Autoimmune Process; Biological; Biological Models; Biological Response Modifiers; Blood Cells; Bone Marrow Transplantation; CD34 gene; CD4 Positive T Lymphocytes; CD8-Positive T-Lymphocytes; CD8B1 gene; Calcineurin inhibitor; Cell Separation; Cell Therapy; Cells; Chronic; Clinic; Clinical; Clinical Protocols; Clinical Trials; Diabetes Mellitus; Disease; Dose; Drug usage; Funding Opportunities; Goals; Graft Rejection; Graft-Versus-Tumor Induction; Health; Hematologic Neoplasms; Hematopoietic; Hereditary Disease; Histocompatibility; Homologous Transplantation; IL2RA gene; IL7R gene; Immune; Immune response; Immunosuppressive Agents; Inflammatory Bowel Diseases; Infusion procedures; Institutional Review Boards; Interleukin-7; Intervention; Laboratories; Laboratory Study; Malignant - descriptor; Minor; Modality; Modeling; Multiple Sclerosis; Mus; Organ Transplantation; Outcome; Patients; Phase; Play; Population; Reaction; Recovery; Recurrence; Regulation; Regulatory T-Lymphocyte; Relative (related person); Research; Risk; Role; Sirolimus; Solid; Speed; Staging; T-Cell Depletion; T-Lymphocyte; Technology; Testing; Time; Tissues; Toxic effect; Translating; Translations; Transplantation; Transplantation Tolerance; Treatment Protocols; base; bone marrow failure syndrome; cell preparation; chronic graft versus host disease; conditioning; effective therapy; graft vs host disease; hematopoietic cell transplantation; high risk; improved; peripheral blood; pre-clinical; receptor; reconstitution; response; transcription factor

DESCRIPTION (provided by applicant): Immune regulation is critical in health and disease. Nowhere is this clearer than following allogeneic hematopoietic cell transplantation where dysregulated immune responses result in graft-versus-host disease (GVHD) and effective immune recognition results in control of the underlying disease, termed graft-versus- tumor effects. In this proposal, we will study the key regulators of immune reactions, namely CD4+CD25+CD127loFoxP3+ regulatory T cells (Treg) which have been demonstrated to have profound effects on control of GVHD in murine models, yet allow for GVT responses. Due to the suppression of the deleterious alloimmune effects which can also impact immune tissues, the use of Treg at defined doses along with conventional CD4 and CD8 cells (Tcon) has also resulted in more effective immune recovery. Further, it has been suggested by a number of studies that Treg can also be used to treat chronic GVHD. Therefore, the aims of this proposal are to directly translate the biological concepts developed in preclinical animal studies to test te hypothesis that the adoptive transfer of highly purified Treg will result in control of GVHD, yet promote accelerated immune reconstitution, as well as treat chronic GVHD. The Proposal involves two clinical trials both utilizing highly purified populations of Treg isolated by high-sped cell sorting through IRB and IND approved clinical protocols. The studies will directly translate important biological concepts from the laboratory to the clinic. If successful the studies could have a major impact on the field of allogeneic hematopoietic cell transplantation and could also set the stage for new treatments of autoimmune disorders and induction of solid organ transplantation tolerance.

描述（由申请人提供）：免疫调节对于健康和疾病至关重要。这一点在同种异体造血细胞移植后最为清楚，其中免疫反应失调会导致移植物抗宿主病（GVHD），而有效的免疫识别会导致对潜在疾病的控制，称为移植物抗肿瘤效应。在本提案中，我们将研究免疫反应的关键调节因子，即 CD4+CD25+CD127loFoxP3+ 调节性 T 细胞 (Treg)，这些细胞已被证明对小鼠模型中 GVHD 的控制具有深远的影响，但又允许 GVT 反应。由于抑制了也会影响免疫组织的有害同种免疫效应，因此将特定剂量的 Treg 与常规 CD4 和 CD8 细胞 (Tcon) 一起使用也可以实现更有效的免疫恢复。此外，许多研究表明Treg还可用于治疗慢性GVHD。因此，本提案的目的是直接转化临床前动物研究中开发的生物学概念，以检验高纯度 Treg 的过继转移将控制 GVHD、促进加速免疫重建以及治疗慢性 GVHD 的假设。 。该提案涉及两项临床试验，均利用通过 IRB 和 IND 批准的临床方案通过高速细胞分选分离出的高度纯化的 Treg 群体。这些研究将直接将重要的生物学概念从实验室转化为临床。如果成功，这些研究可能会对同种异体造血细胞移植领域产生重大影响，也可能为自身免疫性疾病的新疗法和诱导实体器官移植耐受奠定基础。